Aurinia Pharmaceuticals - AUPH Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AUPH shares.
View AUPH analyst ratings or view top-rated stocks.

6 Wall Street research analysts have issued 1-year price targets for Aurinia Pharmaceuticals' stock. Their AUPH share price forecasts range from $13.00 to $26.00. On average, they anticipate the company's stock price to reach $19.75 in the next year. This suggests a possible upside of 157.8% from the stock's current price.
View analysts price targets for AUPH or view top-rated stocks among Wall Street analysts.

Aurinia Pharmaceuticals' stock was trading at $22.87 at the start of the year. Since then, AUPH shares have decreased by 66.5% and is now trading at $7.66.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our AUPH earnings forecast.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced its quarterly earnings results on Thursday, August, 4th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.03. The biotechnology company had revenue of $28.19 million for the quarter, compared to the consensus estimate of $27.07 million. Aurinia Pharmaceuticals had a negative net margin of 178.32% and a negative trailing twelve-month return on equity of 38.01%. During the same period last year, the business posted ($0.37) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY).

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AUPH stock can currently be purchased for approximately $7.66.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a market capitalization of $1.09 billion and generates $45.60 million in revenue each year. The biotechnology company earns $-180,970,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis.

The company employs 300 workers across the globe.

Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The official website for the company is www.auriniapharma.com. The biotechnology company can be reached via phone at 250-708-4272, via email at ir@auriniapharma.com, or via fax at 250-744-2498.